VEW 2022: Cutting-edge therapeutic developments are improving patients' quality of life

Video

Jessica Steen, OD, FAAO, shares highlights from her VEW 2022 presentation, "Ophthalmic therapeutics update."

Jessica Steen, OD, FAAO, assistant professor at Nova Southeastern University College of Optometry where she serves as director of the glaucoma services, sat down with Optometry Times® editor Kassi Jackson to share hightlights from her presentation, "Ophthalmic therapeutics update," which she presented during this year's Vision Expo West in Las Vegas.

This transcript has been lightly edited for clarity:

Jackson:

I'm joined today by Dr. Jessica Steen, assistant professor at Nova Southeastern University College of Optometry, where she serves as director of the glaucoma services. She's here to share highlights from her discussion titled, "Ophthalmic therapeutics update," which she's presenting during this year's Vision Expo West in Las Vegas. Thank you for being here. Dr. Steen.

Steen:

Thanks, Kassi.

In a presentation at Vision Expo West in Las Vegas, I had the opportunity to provide an update—and really most importantly—to provide some clinical context to some of the many newly approved up ophthalmic therapeutic agents.

One of our greatest challenges is really staying on this leading edge of newly available therapeutic options when we're talking about managing ocular disease. Understanding treatment options is so central to really optimizing treatment, but also we have to think about being able to counsel patients who may be undergoing therapeutic interventional treatment with one of our surgical colleagues.

We talk about some of the general trends and development of therapeutics in eyecare, really focusing on first in class agents, repurposed agents, biologics and biosimilars, and also the landscape that these agents are investigated within.

When we're talking about anterior segment disease, we really focus on new routes of administration, new indications for agents that may have previously been used off label or for another ocular condition, and topical agents that may have cosmetic as well as functional benefits.

In the space of glaucoma, we talk about therapeutics that utilize non traditional mechanisms to lower intraocular pressure, and procedure-based therapeutic treatments. And most importantly, hear where each therapy or treatment really may fit into the management of a patient with glaucoma or ocular hypertension.

Within retinal vascular disease, we're at a time where we our surgical colleagues and our patients are so fortunate to have highly efficacious medications that overall have excellent safety profiles, which has shift the focus to expanding developments to agents that have a longer duration of action, and those that utilize additional or alternative targets for really a more well rounded treatment.

And right now we're really at quite an interesting time where we are just starting to enter this space of ophthalmic biosimilar agents. We discussed the recently approved biosimilar anti-VEGF agents and the potential impact that these agents, as well as biosimilars in general, may have to our surgical colleagues, our patients, and certainly to our treatment, as well.

And looking ahead, we are most excited about the positive results of clinical trials evaluating treatment options within this space of geographic atrophy. And this really has us looking forward to a potential new approved agents in the near future, which is certainly going to change the way we manage patients with late stage dry AMD.

So bottom line, we are at a time where therapeutic developments and the approval and availability of new agents is really changing the way that ocular disease is managed and these new agents continue to utilize new targets for treatment, utilize alternative routes for medication administration, and act to, in general, increase the amount of time between treatments, all of which act together to ultimately improve patient quality of life.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.